Azmi Nabulsi - Jul 14, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Chief Operating Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
Stock symbol
PHAT
Transactions as of
Jul 14, 2023
Transactions value $
$0
Form type
4
Date filed
7/17/2023, 05:00 PM
Previous filing
Apr 11, 2023
Next filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award +110K +110.48% 210K Jul 14, 2023 Direct F1
holding PHAT Common Stock 3.58K Jul 14, 2023 by 401(k) F2
holding PHAT Common Stock 786K Jul 14, 2023 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option Disposed to Issuer -70K -100% 0 Jul 14, 2023 Common Stock 70K $32.20 Direct F1
transaction PHAT Stock Option Disposed to Issuer -150K -100% 0 Jul 14, 2023 Common Stock 150K $39.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 1,233.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.